Key issues for the assessment of the allergenic potential of genetically modified foods: breakout group reports. by Germolec, Dori R et al.
On the final afternoon of the workshop
“Assessment of the Allergenic Potential of
Genetically Modified Foods,” held 10–12
December 2001, in Chapel Hill, North
Carolina, speakers and participants met in
breakout groups of 8–12 individuals to discuss
key issues in the following areas: use of human
clinical data, animal models to assess food
allergy, biomarkers of exposure and effect,
sensitive populations, dose–response assess-
ment, and postmarket surveillance. Each
group was asked to address general questions
regarding what can be done to assess the
potential allergenicity of genetically modiﬁed
(GM) foods and what is needed to improve
this process, as well as questions specific to
each particular topic. In many instances, the
discussion topics overlapped such that a num-
ber of topics were addressed by multiple
groups, and in some cases their conclusions
differed. Following is a brief summary of the
discussions of each of the six breakout groups
regarding our current state of knowledge and
what information is needed to advance the
ﬁeld. Each breakout group contained individ-
uals with a wide variety of expertise so that the
subject material could be covered fully. The
text below is an effort to capture the expertise
and opinions of diverse participants and as
detailed in the text below, in some instances
consensus was not achieved.
Use of Human Clinical Data
How important are the following end points
in hazard identification and dose response:
immune indicators of sensitization (IgE, skin
test positivity), clinical symptoms from skin,
gut, respiratory tract after provocation
(DBPCFC), and anaphylaxis? A clinical
syndrome suggestive of an IgE-mediated
reaction (flushing, urticaria, angioedema,
wheeze, stridor, abdominal pain, vomiting,
or cardiovascular collapse) after the ingestion
of an allergenic food can be conﬁrmed with a
skin prick test (SPT) or serum-specific IgE.
However, in the absence of a clinical history
suggestive of allergy, IgE detection, whether
SPT or speciﬁc IgE, serves as a good indica-
tor of sensitization but not necessarily of dis-
ease. Conversely, in the clinical setting, the
absence of detectable IgE may be useful at
excluding IgE-mediated food allergy.
However, this depends somewhat on the spe-
ciﬁc antigen and techniques used. It is possi-
ble to obtain positive SPT results in
individuals who test negative for serum IgE,
as antigen-specific IgE may be predomi-
nantly cell bound when present at low levels.
Interpretation of the usefulness of SPT or
food-specific IgE rests with the comparison
of SPT/speciﬁc IgE results with the outcome
of double-blind, placebo-controlled food
challenge (DBPCFC), which is currently the
“gold standard” for determining food allergy.
Approximately 50% of positive SPTs corre-
late with confirmed DBPCFCs, suggesting
that sensitization to food allergens occurs in
the absence of clinical symptoms (Bock et al.
1977, 1978; Eigenmann and Sampson
1998). The magnitude of the SPT or speciﬁc
IgE measurement is useful in predicting the
likelihood of clinical allergy (as conﬁrmed by
DBPCFC) but is not useful in predicting
severity (Eigenmann and Sampson 1998;
Sampson 2001).
The DBPCFC is an excellent method for
conﬁrming suspected allergy. In a controlled
setting with experienced clinicians, the
DBPCFC can be safely performed (Bock et al.
1978, 1988; Watson 1995; Williams and
Bock 1999). The rapidity of IgE-mediated
reactions (> 90% within 1 hr) allows the
DBPCFC to reproduce objectively IgE-
mediated symptoms resulting from the food
administered.
Theoretically, any food containing a
protein could elicit an allergic reaction; how-
ever, eight common foods are responsible for
> 90% of food allergies. The remaining 10%
of food allergies result from over 150 differ-
ent proteins (Hefle et al. 1996). Data are
becoming available on threshold doses
required to provoke an allergic reaction in
previously sensitized individuals. Recently,
the results of 10 independently conducted
clinical challenge studies have been reported
(Taylor et al. 2002). In these 10 well-deﬁned
clinical studies involving peanut, milk, egg,
fish, and mustard allergens, 0.25 mg peanut
protein (equivalent to 1 mg whole peanut)
was the lowest provoking dose and was there-
fore considered to be the lowest observable
adverse effect level (LOAEL) for elicitation.
Of the 10 studies, one reported four subjects,
from a study cohort of 74, who developed an
allergic response to this LOAEL. In the other
nine studies, no other individuals with this
degree of sensitivity were identiﬁed. It should
also be noted, however, that the responses in
these four individuals were mild and reversed
spontaneously (Taylor et al. 2002).
What end points are appropriate for the
premarket assessment of previously sensitized
individuals to source proteins versus the post-
market assessment of potentially sensitized
individuals to source proteins as well as the
potential sensitization and allergenicity of
novel proteins? In premarket assessment of
novel proteins for hazard identification, the
group fealt tht there was no role for SPT or
measurement of speciﬁc IgE, as sensitization
would not have occurred. However, when the
protein in question originates from a known
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clinical testing would be valuable. Clinical
testing could include specific serum testing
from well-deﬁned allergic individuals and/or
SPT. SPT may only be necessary in situations
where human serum IgE is detected to the
GM protein and the product is to be further
developed. It is expected, however, that in
most circumstances where specific serum
screening is positive, there would not be any
further development of the product.
In a postmarket assessment, if IgE is
detected either serologically or by skin testing,
the relationship between the detected IgE and
clinical symptoms may be confirmed using
DBPCFC.
What constitutes “harm” (a term used in
standards for food safety evaluation by both
the U.S. Food and Drug Administration and
U.S. Environmental Protection Agency)? Is
sensitization harm? What about clinical symp-
toms? What evidence links antigen-speciﬁc IgE
with these responses? Using an accepted legal
deﬁnition of harm as “reasonable certainty of
no harm,” several factors must be considered.
These include at-risk populations, potency
and exposure to the allergen, and background
prevalence of food allergy.
Development of clinical symptoms un-
equivocally constitutes harm, but development
of sensitization does not. Not all individuals
who have IgE against a specific protein will
develop clinical symptoms (Sarlo and
Kirchner 2002). However, IgE-mediated aller-
gic symptoms and signs will not occur in the
absence of sensitization; therefore, sensitiza-
tion leads to the potential for harm. In other
words, if the sensitization can be detected and
if the exposure is removed prior to the occur-
rence of clinical symptoms and signs, harm
may not result. There is evidence to suggest
that sensitization to respiratory allergens in the
occupational setting may occur at lower levels
of exposure than doses capable of eliciting sys-
temic hypersensitivity, and that reduction of
exposure can also remove the chances for
harm (Schweigert et al. 2000). However, res-
piratory tract sensitization may not predict the
risk of allergic sensitization from oral ingestion
in the case of foods. For example, baker’s
asthma is a common occupational disease, yet
very few bakers have allergic responses after
eating wheat bread, even though many have
wheat protein–specific IgE (Smith et al.
2000). Additionally, it has been observed that
some IgE antibodies are not clinically relevant
and will not result in clinical sequelae (Aalberse
et al. 2001).
As discussed above, the positive predictive
value of antigen-speciﬁc IgE, whether SPT or
serum measurements, varies with the food in
question and the disease prevalence. In gen-
eral, the positive predictive value of an SPT
ranges from 25 to 75%.
What kinds of tests can be done in the
clinical setting, and should they be conducted
prior to approval or in the postmarket evalu-
ation? If the gene is derived from a source
known to be allergenic, in vitro studies such
as immunoblots should precede clinical stud-
ies. If IgE binding by the protein in question
is detected, further development should only
proceed with caution. Clinical studies, includ-
ing specific serum screening, and/or SPTs
should be performed prior to marketing.
Speciﬁc serum screening should be performed
with serum obtained from well-deﬁned clini-
cal populations with allergies to the source
protein. The feasibility of this step depends
on the availability of banks that contain sera
from well-deﬁned, clinically allergic individu-
als. SPTs can also be performed to correlate
with the outcome of the specific screening,
but this may not be necessary unless serum
data banks are inadequate or unavailable.
If the gene is derived from a source not
known to be allergenic, no clinical tests are
likely to be relevant in an unexposed popula-
tion. However, as recommended by the Food
and Agriculture Organization/World Health
Organization Expert Consultation (FAO/
WHO 2001), targeted serum screening for
cross-reactivity with sera from patients allergic
to proteins broadly related to the source gene
could be conducted. If cross-reactivity is
found, there may be a role for skin testing of
individuals allergic to the related source pro-
tein with the novel protein. In this scenario, it
may also be important to use appropriate non-
clinical tests, such as animal models with
appropriate positive and negative controls, in
conjunction with human clinical trials. The
ethical and technical constraints of conducting
human trials, and the necessity of doing so, is
a subject that requires considerable attention.
However, these types of studies may be neces-
sary for the validation of animal models as
predictors of human allergic disease.
Postmarket assessment of novel foods.
Clinical testing with specific IgE should be
developed and employed. In addition, SPT
with purified protein would be useful to
detect IgE in vivo. Positive tests should be fol-
lowed by DBPCFC, under appropriate clini-
cal observation, to correlate demonstrable IgE
with clinical symptoms. The availability of
puriﬁed protein may limit the development of
speciﬁc IgE tests.
What evidence, if any, is there for cross-
reactivity between different food allergens and
between respiratory allergens and food aller-
gens? Within food families, there is consider-
able in vitro cross-reactivity. However, this
frequently does not correlate with clinical
cross-reactivity. Bock and Atkins (1990)
described the results of 480 food challenges
where < 1% of the children demonstrated
clinical allergy to more than one member of a
food family. Similarly, Bernhisel-Broadbent
and Sampson (1989) demonstrated that in 41
children with two or more positive SPTs to
legumes, only two of these children had posi-
tive challenges to more than one legume.
Similar data exist for cereal grains, nuts, and
fish (Bernhisel-Broadbent et al. 1992; Bock
and Atkins 1989; Jones et al. 1995). Although
in vitro cross-reactivity greatly exceeds clinical
cross-reactivity, there is signiﬁcant variability
between patients and their reactivity to mem-
bers within food families (Bernhisel-Broadbent
et al. 1989).
Cross-reactivity can also be demonstrated
between foods and aeroallergens, where pol-
lens may cross-react with fruits, vegetables, or
nuts. Examples include birch pollen that cross-
reacts with apples, pears, and cherries, and
ragweed pollen that cross-reacts with gourds.
The potential utility of targeted serum
screening is well described in the FAO/WHO
Expert Consultation Report (FAO/WHO
2001), but widespread use would require
standardized panels of food and inhalant
IgE obtained from individuals with well-
characterized allergies. Although targeted
serum screening may be an appropriate
approach to the detection of potential aller-
gens, many of the tools needed to routinely
conduct this type of testing are not widely
available (e.g., pooled banks of sera from
allergic individuals), and both development
and validation of the associated tests would be
necessary prior to their use for risk assess-
ment. Some IgE epitopes may not be clini-
cally relevant, and such information should
be considered when serum screening is used.
Animal Models to Assess
Food Allergy
What attributes should an animal model
have to be a reasonable method for safety
evaluation of allergic potential? This group
deﬁned allergy (as opposed to immunogenic-
ity) as the adverse health effects that may
result from the stimulation of a specific
immune response. For the purposes of this
discussion the focus was on IgE-mediated
responses induced against dietary proteins
and resulting in food allergy and excluded
such reactions as celiac disease. However, it is
important to note that not all IgE responses
are harmful (e.g., protection against round-
worm infection). Models should be able to
distinguish between immunogenicity (IgG,
IgM, IgA, and cellular immune responses)
and allergenicity (IgE). The participants felt
that to meet this criterion an animal model
would likely be genetically predisposed to
have an atopic or T-helper cell type 2 (Th2)
phenotype involving a skewed response
toward the production of IgE antibodies and
Th2 cytokines [interleukin (IL)-4, IL-5, IL-6,
IL-10, and IL-13].
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antigen (usually protein)-speciﬁc IgE antibod-
ies. There was some discussion regarding pure
carbohydrates as allergens, recognizing that
many allergens are glycosylated proteins. It was
also noted that lipids or oils in highly allergenic
foods such as peanuts and tree nuts might
influence immune responses. For all partici-
pants in this group, the ability to demonstrate
antigen-specific IgE antibodies mediated by
mast cells/basophils was the critical factor in
the utility of any model. Additional markers
such as cytokine or chemokine proﬁles could
be used in conjunction with IgE.
Animal models should focus on hazard
identiﬁcation concerning potential allergenicity
of proteins. As responses measured within the
models may be used to assess the potency of
specific allergens, validation of the models
might include the determination of potency of
known allergens. A second focus of animal
models could then be the assessment of
potency of novel allergens, which may be of
use in risk assessment. Although dog and swine
models are useful for studying mechanisms of
food allergy, as they have clinical manifesta-
tions similar to those seen in humans, they
may be less practical than the use of rodent
models to study hazard identiﬁcation.
Similarly, while adjuvants may be used to
enhance allergic responses for the study of
mechanisms of food allergy and pathology,
the use of adjuvants in models meant for haz-
ard identification should be considered with
caution. It is possible that the use of adjuvants
could confer on nonallergic proteins the abil-
ity to cause sensitization, thus creating false
positives. However, few data are available to
substantiate this hypothesis.
Finally, there must be a great deal of
confidence on the level of false negatives in
any model, as false negatives might lead to an
inappropriate conclusion that a novel food
is safe.
What characteristics must the adminis-
tered allergen have to represent accurately the
risk of effects in humans? Safety evaluation of
foods derived from GM crops is necessary to
ensure that the novel food is as safe as the con-
ventional food. Given this goal, the protein
being tested should be identical, at least as is
practically possible, to the protein expressed in
the plant. For testing purposes, the novel pro-
tein is usually expressed in a vector such as
Escherichia coli or yeast. It must be determined
in advance if molecular differences exist
between proteins expressed in the new crop or
end product and those expressed in the vector.
An additional consideration is whether the
introduced gene results in the expression or
upregulation or alteration of endogenous
genes (thus potentially coding for allergenic
proteins) or results in changes in posttran-
scriptional processing of endogenous proteins
with the potential of creating new allergens.
Finally, the matrix within which the protein
will appear needs to be considered. Is it appro-
priate to test puriﬁed proteins, or should they
be evaluated along with other food compo-
nents as they are seen in the digestive tract?
What are appropriate positive and negative
controls? Positive and negative allergens should
be used to evaluate and validate any model.
There was some controversy among the partici-
pants regarding the use of only pure proteins or
even pure epitopes, such as arachis hypogaea 2
(Ara h2) from peanut, as the sole positive versus
the use of crude protein extracts. Such extracts
would more closely mimic human exposure by
preserving glycosylation and/or binding to nat-
ural adjuvants found in the crop of interest.
Positive controls should be antigens positive in
humans, such as peanut Ara h2 and peanut
lectin, brazil nut 2S-albumin, ovomucoid, oval-
bumin, and β-lactoglobulin. Positive allergens
should induce at least a moderate response and
dose–response relationships should be demon-
strable. Negative controls should be proteins
that the human population is widely exposed to
but seldom lead to allergenic responses such as
rubisco or corn phosphoenolpyruvate–carboxy-
lase. Ideally, both positive and negative controls
should be easily stored, relatively stable, and
reasonably affordable.
What questions can be potentially addressed
using animal models? In addition to questions
regarding the sensitizing potential and relative
potency of individual allergens, animal models
may be used to complement or provide corrob-
orative information for other testing methods.
For example, there is considerable debate about
how much sequence homology is required
with a known allergen in order for a novel pro-
tein to be allergenic and about the relevance of
stability in pepsin as a marker for allergenicity.
Animal models could be used to examine the
properties of foods that have some sequence
homology or pepsin stability to determine if
the novel protein is an allergen, and if so, what
its relative potency would be. In vivo models
could also be used to determine dose–response
relationships and whether there are thresholds
below which allergenic proteins have no clini-
cal effects. In the detergent industry, exposure
levels have been reduced and managed so that
between 0 and 3% of the workforce become
sensitized in a given year (Sarlo and Kirchner
2002; Schweigert et al. 2000). Under these con-
ditions of exposure, clinical disease has been
virtually eliminated, indicating that, at least for
aeroallergens, there is a threshold for sensitiza-
tion that may be different than that for elicita-
tion. Determination of acceptable limits for
both sensitization and elicitation of clinical
symptoms may have important implications
for risk evaluation and management.
Animal models can also be useful tools to
determine basic information on the mechanisms
of the allergic response. The speciﬁc properties
that make a protein an allergen and how toler-
ance is induced are of critical importance in
understanding allergic responses. In vivo models
may elucidate how speciﬁc proteins could be
made to induce tolerance rather than sensitiza-
tion. In addition, these types of models could
provide data on cross-reactivity between speciﬁc
allergens. External factors such as environmental
tobacco smoke, particulate materials, and infec-
tious agents may act as adjuvants to enhance
sensitization. These types of effects are best
examined using in vivo models.
How can data generated in animal studies
be used in the safety evaluation process?
Results of appropriate animal studies pertain-
ing to hazard identiﬁcation and potency eval-
uation can make a signiﬁcant contribution to
the safety evaluation process. These types of
models can be used to screen proteins in con-
junction with information from stability and
in vitro studies.
What are the limitations in current ani-
mal models, and how can we improve them?
Validation studies are needed to assess whether
animal models can accurately predict aller-
genicity in humans. Although allergic re-
sponses in animals and humans share many
common mechanisms, there are clearly some
cross-species differences such as in reaginic
antibodies and complement components that
induce anaphylaxis. Allergy or atopy in both
humans and animals depends on genetic fac-
tors that differ between individuals and
between species. Introduction of novel genes
may alter the metabolism or expression of
endogenous proteins that may differ across
species. Because of genetic differences across
species, the ability to sensitize or alter endoge-
nous protein expression may not readily be
captured in some models. In addition to
species differences, there are questions regard-
ing differences in responses to speciﬁc allergens
between rodent strains.
It is unlikely that a single animal model
will be sufﬁcient to address all the issues con-
cerning prediction of allergenicity to humans.
Rather, some species (such as rodents) that
are less expensive and technically challenging
may provide information on hazard identiﬁ-
cation and statistical validity of nonallergenic-
ity. Other species, for example, dogs and
swine, that more closely follow the clinical
symptoms in the atopic human population
may provide important mechanistic informa-
tion. Although reagents to evaluate allergic
responses, such as cytokines, chemokines, and
monoclonal antibodies to cell surface mark-
ers, are readily available for rodents, they are
only now being developed for dogs and
swine. It is clear that we must evaluate the
currently available animal models, validate
their utility to predict human responses, and
decide how best to integrate one, some, or
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safety assessment.
Biomarkers of Exposure 
and Effect
The appropriateness of measuring antigen-
speciﬁc IgE and other potential biomarkers of
allergy and exposure was considered for both
premarket and postmarket evaluations of the
safety of GM foods. Factors were identified
that were deemed important to the develop-
ment and validation of the recommended
analytical procedures.
What biomarkers are available that can
be applied to safety evaluation and risk assess-
ment of novel foods? Is IgE sufﬁcient? When a
gene is transferred into a food crop, using the
techniques of biotechnology, the newly
expressed protein should be evaluated regard-
ing its potential allergenicity (Metcalfe et al.
1996). If the gene donor organism is known
to be allergenic, or if the amino acid sequence
of the introduced protein is similar to a
known allergen, the potential allergenicity is
most appropriately evaluated by testing for
antigen-speciﬁc reactions in those individuals
with documented allergies to the donor or to
the homologous allergen. Deﬁnitive proof that
a protein is a food allergen would be the
observation of a clinical reaction within a
short time after ingestion of the food, which is
most appropriately performed in a DBPCFC
(Sampson 1997). Because of practical and
safety considerations, a biomarker of potential
effect, such as measurement of antigen-speciﬁc
serum IgE, or positive skin test results may be
more appropriate in the premarket phase of
testing. However, these methods typically
have modest to signiﬁcant levels of false-posi-
tive and false-negative results, which may be
minimized by proper assay design and reagent
selection (Bindslev-Jensen and Poulsen 1997).
A variety of antigen-specific IgE immunoas-
says have been used for preliminary diagnosis
of food allergy. The same type of tests could
also be used to monitor potential allergic reac-
tions once the product is in the marketplace.
The potential utility of other biomarkers
was discussed, including Th2-cell cytokine
expression or proliferation, serum basophil or
mast cell protease levels, and serum histamine
levels. There is little evidence to support the
use of these as biomarkers of allergic responses
to dietary proteins. Measurements of other
antibody isotypes including IgG4, IgA, or
IgM were similarly dismissed as not being
speciﬁc markers of allergic reactions.
In addition to the need for an antigen-
specific IgE assay, the utility of measuring
antigen-speciﬁc IgG was considered. Opinions
were mixed regarding the usefulness of the
expected data except in the case of negative IgE
test results. In that case a positive IgG response
demonstrates that individuals were exposed to
the introduced protein and that this protein
was immunogenic. If they do not have protein-
speciﬁc IgE or IgG, it is difﬁcult to ascertain
whether they were exposed or are just im-
munologically unresponsive to the protein.
Measurement of IgG levels in IgE-positive
individuals is not likely to provide additional
information on exposure or responsiveness.
What parameters are important in assays
used to measure biomarkers of exposure and
effect? Protein standards. For all assays dis-
cussed, the protein used as the test reagent
and/or standard must be appropriate and repre-
sentative of the material that will be in the food
supply. Further, because the introduced protein
in the currently approved GM products are
expressed at low levels (< 1 ppm to ~ 400 ppm
fresh weight), considerable time and effort are
required to produce gram quantities of puriﬁed
protein needed for use in assays and as a stan-
dard for the immunoassays. Because the devel-
opment of GM plants suitable for commercial
production is complex and time consuming, a
recombinant protein produced from bacteria,
yeast, plant, or animal cell culture system will
typically be used. However, both the recombi-
nant protein produced in the plant and in the
heterologous organism will need to be charac-
terized to demonstrate equivalence.
Because the epitopes recognized by some
antibodies are formed by noncontiguous
amino acids in close proximity because of the
secondary structural folding of the antigen,
optimal binding may require native conforma-
tion of the protein used in the immunoassays.
However, a number of the most important
allergenic epitopes found in food allergens
involve only the primary structure and may
require a denatured form for optimal detec-
tion. There is no single correct answer for all
proteins regarding the question of which form
is the correct one to use in evaluating IgE bind-
ing. Further, it is technically impossible to eval-
uate the absolute secondary, tertiary, and
quaternary structure of all proteins in complex
mixtures found in foods. However, as most
proteins puriﬁed from either microbial sources
or plants will be present as a population of
native and denatured forms, antibodies from
exposed individuals or immunized animals are
expected to bind to a substantial fraction of
either form.
With regard to the traceability of the
introduced protein in foods, some proteins are
enzymatically cleaved in the plant or during
processing. Detection of fragments of the pro-
tein in processed foods may therefore not be
possible unless immunoassays are developed
with antibodies that recognize different seg-
ments of the protein. It is therefore recom-
mended that the epitopes recognized by the
antibodies used in these assays be mapped
in order for the limitations of the assay to
be understood. Traceability is important for
exposure assessment in the case of a protein
determined to be allergenic or if certain types
of postmarket surveillance were performed.
Immunoassays. Direct enzyme-linked
immunosorbent assay (ELISA), ELISA inhibi-
tion, direct radioallergosorbent test (RAST),
RAST inhibition, Western blot or Western
inhibition, or similar assay can be used to
measure antigen-specific serum IgE. ELISA
and RAST assays provide quantitative data of
antibody binding to the solid-phase antigen.
These assays have a qualitative measurement
of the antibody–epitope interaction as well
when dose responses and the slope of the
dose–response curves are compared, although
the inhibition assays are most appropriate for
that evaluation. Western blot assays are rarely
used for quantitative measurement but are
quite useful to determine antibody speciﬁcity
and, if appropriate, to evaluate the ability of
the antibody to recognize fragments of the
protein. General considerations for each assay
were discussed in varying detail, with most
emphasis placed on direct ELISA assays.
Appropriate positive and negative controls
must be chosen to verify the specificity of
binding and detection as well as day-to-day
assay reliability. Licensed diagnostic allergy
tests are required to have appropriate positive
controls (NCCLS 1997). However, a direct
positive control for antigen-specific human
IgE is only available if there are individuals
identified who have the specific allergy and
who have signiﬁcantly high titers of antigen-
speciﬁc IgE in their sera. That is not likely to
be the case for novel proteins, as they are
intentionally chosen to avoid known allergens.
Therefore alternative indirect controls must be
used. Animal sera may be used to test for the
presence of the antigen in the assay. Further, a
different allergen-specific IgE assay and sera
may be used to test the speciﬁcity and sensitiv-
ity of detection reagents to allow evaluation of
the test articles and reagents. Antigen-speciﬁc
human IgG may be assayed to evaluate whether
an individual has been exposed to the antigen
and whether the test protein is appropriately
immunogenic. If there are no positive human
sera, animal sera from specifically sensitized
animals may be used to evaluate the protein
antigen and test system.
Selection of subjects for human studies.
Premarket testing may be used to determine
whether allergic subjects who have been previ-
ously exposed to a protein have developed IgE
that binds to the novel protein. Subjects will
normally be consenting adults who have been
identiﬁed through clinical allergy practices or
by speciﬁc searches or surveys. These individu-
als are evaluated by careful interviews and
screening of serum reactivity. The history of
exposure of the serum donors must be clearly
defined and documented. Individuals who
have been occupationally exposed to the novel
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market testing if exposure is clearly defined
and documented. Even if specific IgE were
detected in serum, deﬁnitive proof of allergy
to the novel protein can be achieved only if
the subjects also have clear clinical histories
consistent with the speciﬁc allergy and if con-
trolled challenge tests are positive. However,
allergic responses after occupational exposure,
which is typically through inhalation, may not
be predictive of responses that may result from
oral exposure to a novel protein. For example,
baker’s asthma is a common occupational dis-
ease, yet very few bakers have allergic
responses after eating wheat bread, even
though many bakers have wheat protein–spe-
cific IgE. Identifying a sufficient number of
appropriate subjects may be another hurdle
when designing human studies. Aside from
the major allergens, the prevalence of allergy
to any one complex allergen may be signifi-
cantly less than 1 in 10,000 randomly chosen
individuals. Reactions to a single protein may
be one-third that number. In practice, it is
very difficult to identify 10 soybean-allergic
subjects to provide sera to perform simple
screening assays, even though allergy to soy is
thought to be common (Goodman RE.
Personal communication). 
Postmarket testing could be performed if
there are reports of allergic reactions to speciﬁc
foods produced from the commodity contain-
ing the GM product. Alternatively, new
patients with allergies to appropriate foods may
be asked to participate in a screen to speciﬁcally
evaluate IgE binding to the introduced protein.
As indicated above, it is unlikely that screening
of a randomly chosen population of consumers
would be productive in identifying allergies to a
speciﬁc protein. In postmarket testing, antigen-
speciﬁc IgG may be measured to evaluate expo-
sure of the subjects and immunogenicity of the
protein but should not be considered as a
marker of potential allergenicity, as antigen-spe-
ciﬁc IgG is not considered sufﬁciently robust or
predictive for the diagnosis of allergies. Further,
the only two plausible mechanisms of action
by which IgG binding would cause immediate
allergic disease are through either complement
activation, which may enhance the IgE effect
in mast cells, or receptor-mediated IgG activa-
tion of mast cells, for which the evidence in
human allergic reactions is quite weak,
although some studies demonstrate activity in
rodents (Siraganian 1997). Although there
have been occasional demonstrations of anti-
gen-speciﬁc IgGs that may enhance IgE bind-
ing and allergic responses (Denepoux et al.
2000), other clear studies provide evidence that
IgG antibodies are important in blocking IgE
reactions after allergen-speciﬁc immunotherapy
(van Neerven et al. 1999). Therefore, measure-
ment of antigen-specific IgG has not been
found to correlate with clinical allergy.
Testing of sera from human subjects should
always be done with careful attention to ethical
standards. These include obtaining informed
consent from subjects and the right of the sub-
ject to access the results from their own sera.
How should biomarkers of exposure and
effect be validated? Validation must include
tests to verify the specificity of binding, and
measurement of the dose–response characteris-
tics of the antibodies and protein similar to
what would be required for a clinical diagnostic
assay (NCCLS 1997). Assay performance
should be veriﬁed in an independent labora-
tory. Positive cutoff values must be established
that would indicate probable clinical signifi-
cance, not just a given statistical level above
background. Signiﬁcance scores for commer-
cially available in vitro allergy tests such as the
Unicap or CapRAST system (Pharmacia
Diagnostics, Uppsala, Sweden) (Sampson
2001) may serve as a model for these tests.
Although levels should not be set to the level
found to be 95% predictive of clinical symp-
toms, the cutoff should be high enough to min-
imize false-positive reports. There are many
examples in the literature of positive IgE bind-
ing to proteins that do not seem to cause clini-
cal reactions (e.g., Fujita et al. 2001). Sera from
many individuals without clinically identiﬁable
allergic reactions to foods will contain some
low-level binding to common food proteins.
The IgE in that case is typically much less
abundant than in those with clinical symptoms,
or may have significantly lower affinity for
binding. Some cross-reactivity is due to the
binding of carbohydrate-speciﬁc IgE that is of
questionable clinical signiﬁcance (Aalberse et al.
2001). A positive in vitro IgE reaction is not
necessarily proof that a protein would cause
clinical allergies but would indicate the need to
test by clinical methods for deﬁnitive proof.
Sensitive Populations
What do we currently know about sensitive
populations; what populations do we think are
most at risk? Why? Children are more suscepti-
ble to food allergies than adults and therefore
are most in need of protection from food aller-
gies (reviewed in Sampson 1997). In particular,
because allergies have a genetic component,
children of atopic parents might be at even
higher risk. The age of the child also probably
plays a role, with younger children and infants
being more susceptible. The higher susceptibil-
ity of children in general, and younger children
specifically, may be due to the immature
immune system not being able to develop
tolerance, to higher gut permeability in the
infant, and/or to higher dietary exposure, for
example, from milk- and soy-based formulas
(Sampson 1997). It has been suggested that the
type and patterns of exposure to speciﬁc aller-
gens may be an important factor in the
increased prevalence of food allergy in infants
(Zeiger 2000). In addition, children who have
preexisting food allergies are more likely to
develop allergic reactions to other foods intro-
duced into their diets. Finally, the issue of
exposures to unexpected sources of allergenic
proteins, such as exposure via milk from soy-
fed cattle (“food chain proteins”), needs to
be considered.
Atopic adolescents and adults represent
other potentially sensitive groups. As there is
evidence that people with atopic dermatitis
are more likely to develop allergies from expo-
sure by other routes (e.g., aeroallergens; Burks
et al. 1988), and allergic dermatitis is easily
observed, it is possible that individuals with
atopic dermatitis might serve as sentinels for
food allergies to novel food products.
Workers who process GM food represent a
fourth potentially sensitive population. Data
support the idea that exposure to aerosols of
food products could lead to food allergy (Leser
et al. 2001; Roberts et al. 2002). Sensitization
might occur via dermal, respiratory, or gas-
trointestinal exposure. This population, having
a known exposure, might also be useful from a
research standpoint.
Is in utero exposure or exposure via breast
milk something we need to be concerned about?
In utero exposure and exposure via breast milk
are important considerations. There is sugges-
tive evidence that children can become sensi-
tized via breast milk to food allergens consumed
by the mother (Frank et al. 1999; Hourihane et
al. 1996; Vadas et al. 2001). Studies have found
food antigens present in uterine ﬂuid. Likewise,
speciﬁc IgE has also been found in cord blood.
It is less clear if there are windows of vulnerabil-
ity to sensitization during in utero development.
Is there any evidence for infections or con-
current exposures to agents with adjuvant effects
inﬂuencing the development of food allergies?
Although the role of infections in development
of food allergy is an important issue, deﬁnitive
data on this question are lacking.
There are data suggesting that crypto-
chrome-1 Ac toxin from Bacillus thuringiensis is
a highly potent systemic and mucosal adjuvant
(Vazquez et al. 1999) and that phylogenetically
distant Cry toxins may bind to the same recep-
tors (Shinkawa et al. 1999). However, the
question of whether GM foods or existing food
proteins could have an adjuvant effect, thereby
increasing the allergenicity of other foods, is
still controversial.
Are the strategies currently proposed for
safety evaluation (risk assessment) adequate to
protect sensitive populations? The group agreed
that no realistic strategy has been proposed to
protect the general population, including sensi-
tive populations. Overall, the procedures repre-
sented within the individual steps in the
decision tree need to be better validated. The
use of human serum for screening needs valida-
tion. Although targeted serum screening tests
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identify appropriate individuals to provide
serum. In addition, the use of postmarket sur-
veillance challenge testing (e.g., DBPCFC)
could be a valuable and safe part of the evalu-
ation process with proper study design. The
use of SPTs and DBPCFCs for evaluating
novel food allergens was a controversial topic.
However, the group agreed that the use of
postmarket surveillance skin testing (for detec-
tion of sensitization) and challenge testing
(e.g., DBPCFC for establishing reactivity) pre-
sents minimal safety concerns if done properly,
and therefore the beneﬁts outweigh the risks.
The value of animal testing in evaluating
safety is also an important consideration.
However, currently it is difﬁcult to extrapolate
animal results to human, and more research is
needed to overcome this obstacle.
The group agreed that developing stan-
dards for safety that protect the public, are
acceptable to the public, and are not too
restrictive is an important but difficult goal,
and that it will be impossible to achieve zero
risk. The concept of substantial equivalence
has been applied to other areas of risk assess-
ment, and the group agreed that it could be
applied to the area of food allergy. Novel pro-
teins could be evaluated against a panel of
known food allergens of varying potency as
a framework.
Models of Dose Response
Evidence for thresholds for sensitization and/or
allergic reactions were presented and discussed.
The need for dose–response information in the
regulatory decision-making process was consid-
ered for evaluating the safety of GM crops.
Additionally, the current tools available for
developing dose–response information as well
as factors such as immunologic tolerance and
sensitization doses (e.g., number, dose, route,
etc.) were discussed.
What is the evidence that there are thresh-
olds for sensitization and/or allergic reactions?
Data from food-challenge studies in humans
were provided for a number of the known
allergenic foods (e.g., peanut, shrimp, milk,
egg, soybean, tree nuts) that demonstrated the
existence of a threshold level for eliciting an
allergic reaction to either the food or the
puriﬁed allergenic food protein (Table 1). For
example, Hourihane et al. (1997) and
Wensing et al. (2001) both reported a thresh-
old of 100 µg total peanut protein or 6 µg of
the peanut allergen Ara h2, and a no-observ-
able effect level (NOEL) of between 30 and
50 µg peanut protein or 2–3 µg of Ara h2 in
patients with peanut allergy, using DBPCFCs.
From this study, the authors concluded that
the threshold dose of peanut protein needed
to elicit a response in a group of individuals
allergic to peanuts varies. In patients with egg
allergy, Moneret-Vautrin et al. (1998)
reported a threshold of < 100,000 µg egg and
54,000 µg ovalbumin and a NOEL of
5,000–10,000 µg egg or 5,400 µg ovalbumin,
whereas Sicherer et al. (2000) reported a
threshold of 100,000 µg egg and 54,000 µg
ovalbumin and a NOEL of 100,000 µg of egg
(i.e., the first dose tested). These data are
important for establishing the relative risk asso-
ciated with a potential food allergen. In contrast
to the elicitation phase of allergic reactions, only
limited data are available in humans regarding
food allergens and thresholds for sensitization.
Furthermore, there may be populations or sub-
populations of individuals (e.g., based on age,
ethnicity) that are more sensitive to the induc-
tion or elicitation phase of protein exposure. In
addition, limited data are available from indus-
trial exposures to proteins (i.e., the detergent
industry) regarding thresholds for sensitization
and/or elicitation for aeroallergens that may be
relevant (Schweigert et al. 2000). Thresholds
for sensitization have also been reported in vari-
ous animal models for both dermal (Basketter
et al. 1997, 1999; Kimber et al. 1999) and
respiratory (Hillebrand et al. 1987; Karol 1983)
sensitizers.
Is there a need for dose–response informa-
tion, or is hazard identiﬁcation alone adequate
to warrant regulatory action? The consensus
was that dose–response information was
needed, particularly for setting relative risk.
However, current regulatory action regarding
the potential allergenicity of foods derived from
GM plants is driven predominately by hazard
identification. For example, the food allergy
decision tree developed by FAO/WHO (1996,
2001) involves determining the source of the
gene(s) (is the source of the gene allergenic?),
evaluating the physicochemical characteristics
of the protein (amino acid sequence homology
to known allergens; pepsin resistance) (Taylor
and Lehrer 1996), conducting speciﬁc and tar-
geted serum screening, and using validated ani-
mal models. If one or more of the latter
evaluations is positive, the protein is labeled as
likely allergenic and removed from further con-
sideration. Therefore, the relative risk associated
with such a protein is usually not considered.
What is the role of immunologic tolerance
in establishing dose–response information?
Currently, little is known regarding the mecha-
nisms of immunologic tolerance. The group
concurred that the dose–response curve begins
once tolerance is broken or fails to be estab-
lished. Furthermore, because tolerance to a
particular protein can be induced by both low
and high doses, it was agreed that a wide range
of doses should be used to maximize the
chance of falling within the responsive range of
the dose–response curve.
What tools are available to develop
dose–response information? The current tools
available to develop dose–response infor-
mation include animal models and human
food-challenge studies (Table 1). For both tech-
nical and ethical reasons, it would be very difﬁ-
cult to conduct human food-challenge or
sensitization studies with novel proteins.
Therefore, it was the opinion of the group that
a validated animal model(s) that assesses the
allergenic potential of proteins currently repre-
sents our best tool for establishing dose-
response information. As with humans, the
genetic predisposition of a particular animal
strain may inﬂuence the degree of allergenicity
observed with a particular protein. Thus, it is
important to ensure that haplotypic differences
do not result in misleading results in animal
models. In initial validation studies multiple
strains of the same species could be evaluated to
determine those strains most sensitive and spe-
cific in discriminating between both known
allergenic and nonallergenic proteins.
Is one large sensitization dose the same as
many small sensitizing doses? The group
agreed that one large sensitization dose is not
the same as many small sensitizing doses.
Among the factors that need to be considered
are the age at which the sensitization dose(s)
occurs, the time between sensitizing doses,
and the route(s) of administration of the sen-
sitizing dose. For example, Woolhiser et al.
(2000), using natural rubber latex proteins,
reported differences in latex-specific IgE
immunoblot proﬁles and pulmonary function
between four different sensitization routes.
These authors concluded that the sensitiza-
tion route of exposure might partially deter-
mine the primary allergen(s) and the clinical
symptoms of the allergic response.
Postmarket Surveillance
What tools and strategies are currently avail-
able for postmarket surveillance, and what can
we learn from them? The feasibility of a range
of tools and strategies that could be applied to
postmarket surveillance of foods produced
through biotechnology and their role in pro-
viding information for safety assessment were
considered. Such tools and strategies included
the collection and analysis of case reports of
adverse reactions; conduct of classical epidemi-
ology studies such as cohort, case–control, eco-
logic, and cross-sectional studies (telephone
surveys, food frequency questionnaires); and
clinical trials (DBPCFCs). The identiﬁcation
of highly exposed populations in the context of
speciﬁc foods (e.g., occupational groups, popu-
lations with limited variety in the diet such as
children, infants, ethnic populations) was con-
sidered helpful for the conduct of epidemio-
logic studies. Marketbasket surveys were
discussed as a means of assessing exposure to
specific types of food and would reflect
regional food preferences. It was suggested that
modern technologies such as grocery-scanning
devices could assist in data collection.
However, exposure to GM foods would be
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labeling.
The most useful tool was considered to be
the development of an adverse event report-
ing system that would allow the systematic
collection of case-report data on adverse reac-
tions to foods. This offered the possibility of
identifying sensitized individuals. In the
United States, such data are currently col-
lected through state health departments,
emergency rooms, and self-reporting. The
existing infrastructure limits the capability for
collecting such information. In addition, a
reliable method for detection of recombinant
proteins in food products is essential to estab-
lish that exposure to a protein that is the
suspected cause of an adverse reaction did in
fact occur. It is important to note that this
kind of system is most useful in identifying
individuals sensitized to specific food items
rather than for assessing the potential for GM
food–induced allergy.
For data on adverse food reactions
collected from postmarket surveillance to be
meaningful, they must be compared against
baseline data collected prior to the introduc-
tion of the food under surveillance. It was sug-
gested that such data could be collected from
pilot surveillance projects to reflect regional
food preferences across the country.
DBPCFCs were considered essential as a
postmarket tool for the validation of causation
between a specific food ingredient and an
adverse reaction. Such studies were not con-
sidered useful screening tools to establish the
potential of adverse food responses related to a
particular food. The limitations and issues sur-
rounding the use of such methods were dis-
cussed. These include difficulties associated
with proving the negative (how many people
would need to be tested) and ethical issues
(e.g., the potential for induction of sensitivity
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Table 1. Thresholds for eliciting allergic responses to food proteins.
Food  Allergen Allergen serving Threshold (µg) Symptoms NOEL (µg)
Peanut Ara h2 6% of total proteina 100 peanut protein or 6 Ara h2 Itching of throat, tongue,  30 peanut protein or
(Wensing et al. 2001) and/or lips 1.81 Ara h1
(Wensing et al. 2001) (Wensing et al. 2001)
100 peanut protein or 6 Ara h2 Oropharyngeal itching 50 peanut protein or 3 Ara h2
(Hourihane et al. 1997) (Hourihane et al. 1997) (Hourihane et al. 1997)
Shrimp Tropomyosin No data on level of  0.02 g shrimp equivalents No data 1 shrimp equivalent
shrimp tropomyosin in  per gram ice cream (Daul et al. 1988)b
shrimp equivalents (Daul et al. 1988)b
Milk β-Lactoglobulin 9% of total proteina 100,000 milk or 400,000 Skin, gastrointestinal,  100,000 was the ﬁrst dose 
β-lactoglobulin and/or respiratory (Sicherer et al. 2000)
(Sicherer et al. 2000) reactions
0.5 β-lactoglobulin (breast milk– “Adverse reactions” No data
exposed infantsc)
(FAO/WHO 2001)
43 β-lactoglobulin (breast milk–  Skin, gastrointestinal, No data
exposed infantsc) and/or respiratory
(Host et al. 1988) reactions
Egg Ovalbumin 54% of total proteina < 100,000 egg or 54,000 ovalbumin Atopic dermatitis,  5,000 or 10,000 egg or 5,400
(Moneret-Vautrin et al. 1998) angioedema, asthma, ovalbumin
anaphylactic shock, (Moneret-Vautrin et al.1998)
digestive symptoms
100,000 egg or 54,000 Skin, gastrointestinal, 100,000 was ﬁrst dose of egg
ovalbumin  and/or respiratory (Sicherer et al. 2000)
(Sicherer et al. 2000) reactions
3,330 SDWE  No data 300 SDWE or 180 ovalbumin
or SDWE 1800 (Christie et al. 2001)
ovalbumin (15.1% SDWE)
(Christie et al. 2001)
500 egg protein or 270 ovalbumin  “Adverse reactions” 500 was the ﬁrst dose
(breast milk–exposed infantsc) (FAO/WHO 2001)
(FAO/WHO 2001)
Wheat Sucrose synthetase < 1% of total proteind < 500,000 wheat or 5,000 allergen Skin, gastrointestinal, 500,000 was the ﬁrst dose
(Sicherer et al. 2000) and/or respiratory  (Sicherer et al. 2000)
reactions
Tree nuts Cor a1 No data on level of Cor  1,000 hazelnut meal  No data 1,000 hazelnut meal was 
(hazelnut) a1 allergen in hazelnut (Wensing et al., 2002) the ﬁrst dose
meal (Wensing et al. in press)
Soybean β-Conglycinin 18.5% of total proteind < 500,000 soy Skin, gastrointestinal, 500,000 was the ﬁrst dose
(Sicherer et al. 2000) and/or respiratory (Sicherer et al. 2000)
reactions
Fish Gad c1 0.1% of total proteind 6,000 (codﬁsh or 6 Gad c1 Irritation, itching,  No data
(Hansen and Bindslev- swelling of oropharynx,
Jensen 1992) gastrointestinal symptoms,
or cutaneous reactions
1,000,000 ﬁsh or 1,000 Gad c1 Emesis, oropharyngeal 1,000,000 was the ﬁrst dose
(Helbling et al. 1999) symptoms, urticaria,  (Helbling et al. 1999)
or respiratory reactions
< 500,000 ﬁsh or 500 Gad c1 Skin, gastrointestinal, 500,000 was the ﬁrst dose
(Sicherer et al. 2000) and/or respiratory (Sicherer et al. 2000)
reactions
SDWE, spray-dried whole egg. 
aData from Metcalfe et al. 1996. bDose levels were 1, 4, or 16 g shrimp equivalents. NOEL was 4 g shrimp equivalents/207 g ice cream. No effects were elicited in this cohort with 1 g
shrimp equivalents/207 g ice cream (Daul et al. 1988). cResults from infants exposed to these allergens in mother’s breast milk. These studies are not applicable to nonnursing children or
to adults. dSoybean allergen expressed in soy milk.in previously unexposed individuals or induc-
tion of life-threatening allergic response in the
process of screening).
When should postmarket surveillance be
done? The issue of whether the conduct of
postmarket surveillance should be routine for
foods produced through biotechnology or
should be triggered by a speciﬁc event in rela-
tion to a particular food (as in the case of
StarLink corn) was discussed by the breakout
group. Participants with concerns about the
uncertainties inherent in the current proce-
dure for allergenicity assessment of recombi-
nant proteins favored routine monitoring. In
contrast, a number of participants were conﬁ-
dent that the present assessment process was
adequate to identify novel proteins with aller-
genic potential and supported the use of post-
market surveillance only when triggered by a
speciﬁc event.
What tools are needed to improve our
ability to do postmarket surveillance and
interpret results? The most useful tool was
considered to be the collection of case reports
of adverse responses to food. Modiﬁcation of
existing adverse events reporting systems was
suggested for this purpose. Among the fea-
tures of such a system that needed to be deter-
mined were a) establishing who would be
responsible for notifying, b) who should be
notified, and c) who would be responsible
for following up the case reports to collect
necessary information. In terms of the current
infrastructure available for the collection of
these kinds of data, two scenarios were envi-
sioned: improvements to the current system
to capture data that would assist assessment of
foods produced through biotechnology, or
developing an entirely new system for collec-
tion and analysis of data. Creation of a non-
proﬁt industry association group such as the
Drug Safety Alliance that would be provided
with access to the desired information
was suggested.
Several members of the group felt that
exposure assessment would be assisted by label-
ing foods produced through new technologies,
but this clearly was an area in which consensus
was not reached. Difficulties were acknowl-
edged in using such labeling in products con-
taining commodity crops in which mixing of
harvested crops from different suppliers is a typ-
ical practice. Foods in which identity preserva-
tion is part of the marketing strategy, as in cases
of nutritional modiﬁcation or allergen reduc-
tion of products, were considered to be more
amenable to labeling.
The lessons of previous experience, (e.g.,
from events where products not accepted for
human consumption were found in consumer
products) were considered useful in terms of
guiding development of postmarket strategies.
Such strategies would beneﬁt from the adop-
tion of a multidisciplinary approach.
Overall Summary
Each breakout group addressed speciﬁc issues
in the areas of use of human clinical data, ani-
mal models to assess food allergy, biomarkers
of exposure and effect, sensitive populations,
dose–response assessment, and postmarket
surveillance. These groups discussed the ade-
quacy of the current tools available for assess-
ment of the allergenic potential of novel foods
and described how these tools need to be
improved for better safety assessment. In sev-
eral instances the groups reached different
conclusions or could not agree on the utility of
specific tools, such as the use of human sera
for hazard identification or labeling of foods
containing GM crops. Each group was asked
to identify specific areas in which data gaps
should be the focus of future efforts. These
research needs are discussed in detail in the
article by Selgrade et al. (2003).
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